December 14, 2020 06:55 AM ESTUpdated 12:03 PM
Coronavirus

Covid-19 roundup: Trump walks back plans to pri­or­i­tize White House staff for vac­cine; As­traZeneca drops sub­group of chil­dren from vac­cine tri­al — re­port

Amber Tong

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

As Amer­i­cans wait to re­ceive the first dos­es of Pfiz­er and BioN­Tech’s re­cent­ly au­tho­rized Covid-19 vac­cine, Pres­i­dent Don­ald Trump is walk­ing back plans for White …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times